


Supplementary figure 1: relative proportion of disease indications for HCT in 2023.
Green shades: myeloid malignancies, blue: lymphoid malignancies, brown: solid tumors and red: non malignant disorders.

1a: allogeneic 1st HCT



1b: autologous 1st HCT.

